First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.

about

First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.

Item

http://www.wikidata.org/entity/Q53068022

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

First report of clinical respo ...... failure of standard therapies.

@en

First report of clinical respo ...... failure of standard therapies.

@nl

type

Item

label

First report of clinical respo ...... failure of standard therapies.

@en

First report of clinical respo ...... failure of standard therapies.

@nl

prefLabel

First report of clinical respo ...... failure of standard therapies.

@en

First report of clinical respo ...... failure of standard therapies.

@nl

P1476

First report of clinical respo ...... failure of standard therapies

@en

P2093

Basile Nicolas Landis

http://www.w3.org/2001/XMLSchema#string

Denis Migliorini

http://www.w3.org/2001/XMLSchema#string

Diego Aguiar

http://www.w3.org/2001/XMLSchema#string

Minerva Becker

http://www.w3.org/2001/XMLSchema#string

Nicolas Mach

http://www.w3.org/2001/XMLSchema#string

Pierre-Yves Dietrich

http://www.w3.org/2001/XMLSchema#string

Rémi Vernet

http://www.w3.org/2001/XMLSchema#string

Valérie Dutoit

http://www.w3.org/2001/XMLSchema#string

P2860

Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer

Chordoma and chondrosarcoma gene profile: implications for immunotherapy

Adaptive Immune Resistance: How Cancer Protects from Immune Attack

Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

Genetic basis for clinical response to CTLA-4 blockade in melanoma

PD-1 blockade induces responses by inhibiting adaptive immune resistance

PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment

P304

e1338235

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/2162402X.2017.1338235

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

T McKee

P577

2017-06-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28919999

http://www.w3.org/2001/XMLSchema#string

P921

chordoma

immunotherapy

P932

5593713

http://www.w3.org/2001/XMLSchema#string